Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure

PI3Kδ is a key mediator of B-cell receptor signaling and plays an important role in the pathogenesis of certain hematological malignancies, such as chronic lymphocytic leukemia. Idelalisib, which targets PI3Kδ specifically, is the first approved PI3K inhibitor for cancer therapy. Recently, we carrie...

Full description

Bibliographic Details

Published in:	Molecules
Main Authors:	Wenqing Jia, Shuyu Luo, Wennan Zhao, Weiren Xu, Yuxu Zhong, Dexin Kong
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Subjects:	PI3Kδ inhibitor virtual screening lead scaffold cancer
Online Access:	https://www.mdpi.com/1420-3049/27/19/6211